Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressive Drug Bioequivalence in Kidney Transplant Recipients – Prograf and CellCept
2025-521800-22-00Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Jul 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus, mycophenolate mofetil and controlled-ileal-release nicotinic acid in Kidney allograft status (RTx) and solid organ transplantation (SOT) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Tacrolimus and mycophenolic acid AUC0-12 and Cmax test:reference ratio. Started Jul 2025; status: completed.
02
Drugs
tacrolimusmycophenolate mofetilcontrolled-ileal-release nicotinic acid
03
Conditions
Kidney allograft status (RTx)solid organ transplantation (SOT)
Beyond the preview
Go deeper on 2025-521800-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521800-22-00.